Home/Pipeline/ELSA-seq / OverC™ Multi-Cancer Detection Blood Test

ELSA-seq / OverC™ Multi-Cancer Detection Blood Test

Multi-Cancer Early Detection (MCED)

Clinical ValidationActiveNCT04825834

Key Facts

Indication
Multi-Cancer Early Detection (MCED)
Phase
Clinical Validation
Status
Active
Company

About Burning Rock Biotech

Burning Rock Biotech is a publicly-traded, commercial-stage diagnostics company specializing in precision oncology. Its core mission is to transform cancer treatment through early detection and personalized therapy selection using advanced genomic profiling. The company has established a significant commercial footprint in China with its portfolio of NGS-based in-vitro diagnostic (IVD) products and laboratory-developed tests (LDTs), while actively developing its multi-cancer early detection (MCED) pipeline. Its strategic direction involves expanding its product portfolio, pursuing regulatory approvals, and exploring international markets.

View full company profile

Therapeutic Areas

Other Multi-Cancer Early Detection (MCED) Drugs

DrugCompanyPhase
Galleri® TestGRAILApproved/Commercial
Early Cancer DetectionPersonalisResearch